L acunar strokes have high disability rates and are the leading cause of vascular dementia. [1] [2] [3] [4] [5] [6] The causes of lacunar strokes are believed to be lipohyalinosis and microatheromas in the small cerebral vessels. [7] [8] [9] The risk factors that have been identified for ischemic stroke do not account for a considerable number of stroke cases, thereby increasing the importance of identifying novel risk factors for stroke. 10 Moreover, little is known about secondary prevention after a lacunar stroke, despite the frequency and burden of lacunar strokes.
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March 2016 (CRP) levels were identified as a risk factor for recurrent stroke and vascular events after a lacunar stroke. 18 In this analysis, we aimed to investigate whether several other inflammatory biomarkers representing innate and adaptive immunity are independent risk factors for prognosis after lacunar stroke, before and after adjusting for potential confounders.
Methods
The methodology for LIMITS, an ancillary study to the SPS3 trial, has been described in detail previously. 19, 20 SPS3 was a multicenter, investigator-initiated, National Institutes of Health/National Institute of Neurological Disorders and Stroke-funded Phase III trial of the secondary prevention of stroke recurrence after a small vessel ischemic stroke. The ancillary study, LIMITS, involved the collection of plasma and serum samples at baseline and at 1-year (≤18 months) follow-up during the study. The plasma and serum samples were stored and analyzed for inflammatory marker levels. The blood samples were drawn at least 3 weeks after the primary stroke event occurred.
Inclusion and Exclusion Criteria
This ancillary study included patients enrolled into the SPS3 trial at sites participating in LIMITS with all patients eligible for SPS3 eligible for LIMITS (45 sites [54% of the SPS3 sites]). Patients were eligible if they had a clinical diagnosis of magnetic resonance imaging-proven lacunar stroke in the absence of a cortical or large subcortical stroke, carotid stenosis or cardioembolic source. LIMITS was approved by the Columbia University Medical Center IRB and by IRBs at all participating sites, with written informed consent obtained from all study participants.
Blood Collection Kits, Phlebotomy, and Local Processing
Participating sites were provided with materials for collection and shipping of blood specimens, including a 10-cc blood sample in EDTA and a 9.5-mL gel serum separator tube. The samples were drawn on the day of randomization, but before the initiation of antiplatelet therapy. Samples were centrifuged on site, and samples were aliquotted and frozen locally before being shipped to the central laboratory at Columbia University. Plasma samples were analyzed in batches blinded to treatment and outcome.
Outcomes
The coprimary outcomes of this analysis were recurrent ischemic stroke and a major cardiovascular event (recurrent ischemic stroke, myocardial infarction, or vascular death). Ischemic strokes were defined as a clinical syndrome of rapidly developing symptoms or signs of focal loss of cerebral function with symptoms lasting >24 hours and no apparent cause other than the ischemic vascular origin. 19, 20 The definition of other vascular events was previously described in the SPS3 trial reports. 1, 21 Additional analyses were performed for the outcome of ischemic or hemorrhagic stroke. Hemorrhagic strokes were defined as neurological deficits associated with intraparenchymal or subarachnoid hemorrhagic lesions confirmed by computed tomography, magnetic resonance imaging, or autopsy.
Statistical Analysis and Sample Size Calculations
Descriptive statistics were calculated for patients in the ancillary LIMITS study, and levels of inflammatory biomarkers were compared across different patient characteristics. ANOVA was used to determine if there were differences in marker categories for continuous variables, a χ 2 test for nominal categorical variables, and Cochran-Mantel-Haenszel when categorical variables were ordinal. For the analyses of primary outcomes, biomarker values at baseline were considered the independent variable of primary interest. Levels of the biomarkers were log-transformed to stabilize the variance. Cox proportional hazards regression was used to estimate the unadjusted hazard ratio (HR) for the biomarkers with time-to-event for ischemic stroke as the dependent variable. Multivariable Cox proportional hazards regression was then used to estimate the adjusted HR for biomarkers after adjusting for additional potential risk factors, including age, sex, race-ethnicity, region, and traditional stroke risk factors defined either dichotomously (hypertension, cardiac disease, diabetes mellitus, and smoking) or continuously (body mass index, high-density lipoprotein, and low-density lipoprotein). Because statin therapy may influence the levels of biomarkers as well as outcomes, analyses were further adjusted for statin use. We considered the time until event as our primary outcome, and those who did not have an event were censored at time of the last observed follow-up visit. In addition to the analyses of the biomarkers as continuous variables, additional analyses were conducted using quartiles of the biomarker levels as the independent variable with the lowest quartile the reference group.
A sample size of 1440 (57% of the initial planned total of 2500 patients to be enrolled in SPS3) was chosen based on feasibility, assuming that ≈40 enrolling centers would enroll at least 12 patients annually for 3 years. All hypothesis tests performed during the analysis of the primary and secondary end points are 2-sided and use an α of 0.05. Table 1 provides median biomarker values by characteristics of LIMITS study participants. There were a total of 1016 subjects with IL-6 values collected at baseline. The distribution of sex differed across IL-6 quartiles (P<0.01), as did the distributions of smoking (P<0.01; Table I in the online-only Data Supplement). There were a total of 628 subjects with monocyte chemoattractant protein (MCP) values collected at baseline. The distribution of age differed across MCP1 quartiles (P<0.01), as did the distributions of race (P<0.01) and region (P<0.01; Table II in the online-only Data Supplement).
Results

Distribution of Inflammatory Markers and Characteristics of the Cohort
There were 1008 subjects with SAA values collected at baseline. The distribution of sex differed across SAA quartiles (P<0.01), as did the distributions of region (P=0.02) and high-density lipoprotein ( Table III in the online-only Data Supplement). There were a total of 1017 subjects with TNF-α receptor 1 (TNFR1) values collected at baseline. The distribution of sex differed across TNFR1 quartiles (P<0.01), as did the distributions of age (P<0.01), region (P=0.02), hypertension (P=0.04), and diabetes mellitus (P<0.01; Table IV in the online-only Data Supplement).
There were a total of 1015 subjects with CD40 ligand (CD40L) values collected at baseline. The distribution of race differed across CD40L quartiles (P<0.01), as did the distributions of region (P<0.01), hypertension (P=0.01), ischemic disease (P<0.01), and diabetes mellitus (P<0.01; Table V in the online-only Data Supplement).
IL-6 and Recurrent Events
In unadjusted analyses, IL-6 was significantly related to the risk of having a recurrent ischemic stroke (adjusted HR per SD, 1.1; 95% confidence interval [CI], 1.0-1.2; P<0.01; Table 2 ). After adjusting for age, sex, race, and region, comorbidities and statin use at baseline, the same associations persisted ( Table 2 ). IL-6 was also associated with an increase in risk of major vascular events (adjusted HR per SD, 1.1; 95% CI, 1.02-1.19; P=0.008).
There was no interaction between assigned antiplatelet treatment and IL-6, considered as a continuous variable, with regard to any of the outcome events. In categorical analyses, however, there was evidence that the treatment effect of dual antiplatelet therapy depended on IL-6 levels (P for interac-tion=0.04 for major vascular events). The risk of recurrent events for patients with IL-6 levels in Q3 (>2.30 and <3.58 pg/L) was significantly higher than for those with the lowest IL-6 level (<1.58 pg/L) in the aspirin therapy+clopidogrel treatment group (for ischemic stroke and major central nervous system hemorrhage: HR, 2.93; 95% CI, 1.15-7.43; P=0.02 and for major vascular events: HR, 3.01; 95% CI, 1.27-7.12; P=0.01). After adjusting for age, sex, race, and region, comorbidities and statin use, there was no longer a significant association in the categorical analysis (Tables 3  and 4 ). IL-6 was not related to the risk of recurrent lacunar stroke ( Table 5 ). There was an interaction between antiplatelet treatment assignment and IL-6 quartiles; as IL-6 quartiles increased, dual antiplatelet therapy became relatively less effective than aspirin alone. There was no interaction between IL-6 and time interval from stroke to blood draw.
TNFR1 and Recurrent Events
In unadjusted analyses, TNFR1 was associated with the risk of having a recurrent ischemic stroke (HR per SD, 1.20; 95% CI, 1.0-1.4; P=0.024) and a major vascular event (HR per SD, 1.20; 95% CI, 1.1-1.4; P=0.002). After adjusting for demographics and comorbidities, TNFR1 was no longer associated with the risk of recurrent ischemic stroke (HR per SD, 1.20; 95% CI, 0.97-1.4; P=0.11) but remained associated with the risk of major vascular events (adjusted HR per SD, 1.21; 95% CI, 1.05-1.41; P=0.01).
Compared with the bottom quartile (TNFR1<2.24 ng/L), those in the top quartile of TNFR1 (>3.63 ng/L) were at twice 
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March 2016 the risk of major vascular events after adjusting for demographics (partially adjusted HR, 1.98; 95% CI, 1.11-3.52), though the effect attenuated after adjusting for other risk factors and statin use (fully adjusted HR, 1.68; 95% CI, 0.93-3.04). There was no evidence that TNFR1 was related to the risk of having recurrent lacunar stroke ( Table 5 ). The risk of having a recurrent major vascular event associated with antiplatelet treatment assignment depended on TNFR1 concentration. There was an interaction between antiplatelet treatment assignment and TNFR1 (P=0.008; Figure) ; as TNFR1 concentrations increased, dual antiplatelet therapy became relatively less effective than aspirin alone.
SAA and Recurrent Events
In unadjusted analyses, SAA, either as a continuous or categorical variable, was not related to the risk of having a recurrent ischemic stroke or a major vascular event. After adjusting for sex, race, region, comorbidities and statin use at baseline, however, SAA was associated with a minimally increased risk of recurrent lacunar stroke (HR per SD SAA, 1.01; 95% CI, 1.00-1.01; P=0.03; Table 5 ). There were no interactions between treatment assignment and SAA.
MCP1 and CD40L and Recurrent Events
Neither MCP1 nor CD40L, either as continuous or categorical variables, was related to the risk of having recurrent events. There was no evidence of an interaction between either MCP1 or CD40L with antiplatelet treatment assignment.
Discussion
We investigated whether several inflammatory markers were independent risk factors for recurrent vascular events, including ischemic stroke, among patients with lacunar stroke in the SPS3 trial. We found that IL-6 and TNFR1 concentrations were associated with the risk of recurrent ischemic stroke and major vascular events. We were unable to demonstrate an association with recurrent lacunar stroke, but our power was limited for this outcome. Other markers, such as MCP1, SAA and CD40L, were not associated with recurrent ischemic stroke or other vascular events. We further investigated whether there was evidence that inflammatory markers could be used to help identify a group of patients with lacunar stroke who might benefit from dual antiplatelet therapy with aspirin and clopidogrel, which has not been shown to be of benefit in patients with unselected lacunar stroke. We found that among recent lacunar stroke patients, IL-6 and TNF receptor concentrations predict risk of recurrent vascular events, and are associated with the effect of antiplatelet therapies.
The relationship between IL-6 and recurrent events that we found in LIMITS was consistent with previous research. For every increase in the SD of IL-6, the risk of recurrent ischemic stroke or major vascular event increased 
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March 2016 by 10%. Previous prospective studies identified a similar relationship between increased IL-6 and recurrent stroke or myocardial infarction. [22] [23] [24] [25] IL-6 is the major cytokine that stimulates the liver to produce CRP, and it is therefore in some ways not surprising that IL-6 would also be associated with an increase in risk of recurrent events in this same cohort. The relationship between IL-6 and recurrent stroke risk, however, was not as robust as the relationship found with high-sensitivity CRP, as quartiles of IL-6 were not associated with recurrence risk after adjusting for other risk factors. The relationship between CRP and IL-6 as predictors of risk, however, may be complicated by bidirectional feedback loops in the regulation of IL-6 and CRP production. In the Northern Manhattan Study (NOMAS), for example, those with the combination of elevated levels of IL-6 and high-sensitivity CRP were found to be at highest risk of a first ischemic event. 26 TNFR1 has been associated with an increased risk of vascular events and mortality in several studies. 27, 28 In NOMAS, TNFR1 was also associated with carotid atherosclerosis, 29 and increased levels were identified as a risk factor for poor outcome after stroke in studies in other populations. 30 In the present lacunar stroke patient cohort, TNFR1 levels predicted recurrent vascular events, including ischemic stroke, but these results were attenuated once the models were adjusted for other potentially confounding covariates. It is thus possible that some of the positive findings from other studies were also because of residual confounding.
We could not confirm that several other inflammatory biomarkers are associated with recurrent ischemic stroke and vascular events, in contrast to previous research. The mechanisms of lacunar stroke, which include liphyalinosis and microemboli, as well as microatheroma, may be sufficiently distinct from those of atherosclerotic disease that predictive variables differ. Although there is emerging evidence that inflammation plays an important role in small vessel disease, these biomarkers related to atherosclerotic disease may not be optimally suited to measure this risk. The associations of inflammatory biomarkers may differ between essentially healthy populations and those who have already experienced a first stroke. There is growing evidence, for example, that the effects of stroke itself may lead to prolonged elevation in inflammation, lasting months or more. 31 Alternatively, there may be other explanations for our inability to confirm MCP1, SAA, and CD40L as risk factors for recurrence in patients with lacunar stroke, including laboratory error, confounding by other key variables, and small sample size.
The reason for the differential effect of intensity of antiplatelet therapies among those with higher concentrations of IL-6 and TNFR1 remains uncertain. We hypothesized that those with more inflammation (ie, higher marker levels) would have a greater benefit from dual antiplatelets 
March 2016 than those with less inflammation. We found, however, the opposite: dual antiplatelets were more effective among those with lower concentrations of inflammatory markers. As levels increased, aspirin alone was more effective. It is possible that among those with higher levels of inflammation, the addition of clopidogrel provided no further benefit beyond aspirin alone. The increased risk associated with inflammation may have been more determinative of an adverse cardiovascular outcome, and less subject to reduction by a second agent. Future studies would be needed to confirm that lower inflammatory marker levels could be used as a criterion for dual antiplatelet treatment after ischemic stroke and lacunar stroke in particular. There are other potential explanations, as well, however. It has been hypothesized that aspirin's vascular protective effects are because of its antiplatelet and anti-inflammatory effects, 32 whereas clopidogrel has primarily antiplatelet effects.
Our study had limitations. Selection bias could have occurred because of the nesting of LIMITS within SPS3. There was also limited data on chronic inflammatory diseases and clinical infections. A further limitation is the use of specifically selected biomarkers as opposed to a more extensive omics-based approach. This study also has strengths, however. First, LIMITS had a multicenter, international design with a central laboratory, which should have reduced interlaboratory error. The population included in this study is diverse with a well-defined lacunar stroke population. As previous reviews of the role of inflammatory biomarkers in stroke management have suggested, similarly designed studies are needed. 33 LIMITS suggests that elevations in the inflammatory biomarkers IL-6 and TNFR1 marginally increase the risk of recurrent vascular events, whereas elevations in the markers MCP1, SAA, and CD40L are not associated with recurrent vascular events. Future studies are needed to further explore and identify risk factors for recurrent vascular events after a lacunar stroke event.
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